Back to Search
Start Over
High Expression of Somatostatin Receptors 2A, 3, and 5 in Corticotroph Pituitary Adenoma
- Source :
- International Journal of Endocrinology, Vol 2018 (2018)
- Publication Year :
- 2018
- Publisher :
- Hindawi Limited, 2018.
-
Abstract
- The development of somatostatin analogs for the treatment of pituitary Cushing’s disease has been based on somatostatin receptor expression analyses of small cohorts of pituitary adenomas. Additionally, the classification of pituitary adenomas has recently changed. To enable progress with this treatment option, we assessed somatostatin receptors in a large cohort of corticotroph and other pituitary adenomas according to the new WHO classification of endocrine tumors. Paraffin-embedded tumor samples of 88 corticotroph pituitary adenomas and 30 nonadenomatous pituitary biopsies were analyzed after processing into tissue microarrays and immunohistochemical staining for SSTR 1, SSTR2A, SSTR3, SSTR4, and SSTR5. For comparison, 159 other noncorticotroph pituitary adenomas were analyzed. SSTR3 expression was higher in corticotroph adenomas compared to PIT-1-positive, gonadotroph, and nonfunctioning pituitary adenomas (p
- Subjects :
- Diseases of the endocrine glands. Clinical endocrinology
RC648-665
Subjects
Details
- Language :
- English
- ISSN :
- 16878337 and 16878345
- Volume :
- 2018
- Database :
- Directory of Open Access Journals
- Journal :
- International Journal of Endocrinology
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.00da7dc58a364ef08c125e71a7d5afbe
- Document Type :
- article
- Full Text :
- https://doi.org/10.1155/2018/1763735